Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

France's Servier has emerged as the suitor, with an all-cash offer to buy Day One and its fast-growing brain cancer therapy Ojemda (tovorafenib) for $21.50 per share, valuing the California company at ...

When the performance of AI models was assessed within stratified patient subgroups, such as only high-grade breast cancers or only MSI-positive tumors, accuracy fell substantially, revealing that the ...

Artificial intelligence tools are increasingly being developed to predict cancer biology directly from microscope images, promising faster diagnoses and cheaper testing. But new research from the ...

Earnings over $24,480 (2026) before full retirement age reduces Social Security benefits. Claimed Social Security early; half of earnings above the threshold are withheld. Benefits recalculated at ...

India, March 2 -- University of Warwick research warns that popular deep learning systems trained for cancer pathology may be relying on hidden shortcuts rather than genuine biological signals.

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to ...

Traditional FDA approval covers encorafenib plus cetuximab with fluorouracil-based chemotherapy for adult metastatic CRC with BRAF V600E mutations confirmed by an FDA-authorized test. BREAKWATER ...

Traditional approval was supported by BREAKWATER, a randomized, open-label phase 3 study in first-line BRAF V600E–mutant metastatic CRC comparing encorafenib/cetuximab plus chemotherapy against ...